3 results
This non-controlled multicentric phase II study is designed to assess the safety and to describe (in relation to children of higher age) the pharmacodynamics of recombinant ASNase for first-line treatment of infants (< 1 year of age at…
Since coughing is the major symptom in BE, the objective of this trial is to evaluate the clinical efficacy of ICS/LABA treatment in subjects with BE on coughing. The primary outcome variables of interest is the Leicester cough questionnaire (LCQ),…
This multicentre phase III study is designed to assess the efficacy and safety of recombinant versus E-Coli derived Aaparaginase from Medac, during treatment of children with newly diagnosed ALL according to the DCOG ALL-10 protocol.Futhermore: To…